RENALYTIX AI

RENALYTIX AI

Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health S... ystem to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.

Renalytix Ai_logo

Industry:
Organization

Address:
Avon House, Cardiff, United Kingdom Zipcode CF64 2EZ

Country:
United Kingdom

Phone:
44 20 3139 2910

Market Cap:
881.39M
Total Assets:
41.3M
Total Cash:
13.29M

Headquarters: PENARTH


Key Executives
Name Title Pay Year Born
Mr. James R. McCullough M.B.A. CEO & Exec. Director 487,721$ 1968(52 years old)
Mr. Fergus Fleming CTO & Exec. Director 339,946$ 1967(53 years old)
Mr. Thomas H. McLain Pres N/A 1959(61 years old)
Mr. Oliver James Sterling III Chief Financial Officer N/A N/A
Dr. Sally Bowden Head of Regulatory Affairs & CBO N/A 1970(50 years old)
Mr. Baljit Singh Head of Clinical Operations N/A N/A
Dr. Michael J. Donovan Chief Medical Officer N/A 1954(66 years old)
Salim Hamir Company Sec. N/A N/A



Financial & Stock
Company's stock symbol is RNLX. Lastest price : 25.64. Total volume :75.61k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.renalytixai.com

  • Host name: ip-148-72-26-208.ip.secureserver.net
  • IP address: 148.72.26.208
  • Location: Scottsdale United States
  • Latitude: 33.6013
  • Longitude: -111.8867
  • Metro Code: 753
  • Timezone: America/Phoenix
  • Postal: 85260

Loading ...
Loading ...


More informations about "Renalytix Ai" on Search Engine

Home | RenalytixAI

Renalytixai.com RenalytixAI is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs. Our goal is to lower healthcare costs and improve patient quality of life by transforming the paradigm for kidney disease risk assessment and clinical management through our KidneyIntelX platform.

Home | RenalytixAI

Renalytixai.com Who we are. RenalytixAI is an artificial intelligence-enabled in vitro diagnostics …

Home | RenalytixAI

Renalytixai.com Prior to joining Renalytix AI, he held leading positions, including as Chief Executive …

Home | RenalytixAI

Renalytixai.com As of 31 July 2020, the Company's issued and fully paid share capital consists of …

Home | RenalytixAI

Renalytixai.com Renalytix AI. Media Enquiries Sara Kienke Tel: 801-447-2698 [email protected]

Home | RenalytixAI

Renalytixai.com Renalytix AI announces the completion of a joint venture partnership agreement with …

Home | RenalytixAI

Renalytixai.com Title Author(s) Publication; Nephrology consultation and mortality in people with …

Home | RenalytixAI

Renalytixai.com The Investor Relations website contains information about Renalytix AI plc's …

Investors | RenalytixAI

Renalytixai.com Nov 01, 2018 · © 2018 Renalytix AI plc. Registered office: Avon House, 19 Stanwell Road, Penarth, Cardiff CF64 2EZ. Registered in England No 11257655.

Renalytix AI plc (RNLX) Stock Price, News, Quote & History

Finance.yahoo.com About RenalytixAIRenalytixAI (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and ...

RenalytixAI and Joslin Diabetes Center Build on

Globenewswire.com 2 days ago · NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announced today that it has entered into an exclusive option agreement with Joslin Diabetes Center for ...

RenalytixAI to Collaborate with AstraZeneca to Improve

Globenewswire.com Aug 21, 2020 · NEW YORK, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), today announced a collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to develop and launch precision ...

KidneyIntelX | AI Kidney Disease Test | RenalytixAI

Kidneyintelx.com KidneyIntelX is the only clinical diagnostic tool available that assesses the risk of progressive kidney function decline in CKD patients with type 2 diabetes. AI-driven insights provide a personalized patient risk score, allowing physicians to improve monitoring and ongoing treatment.

RENALYTIX AI PLC (RTNXF) Stock Price, News, Quote

Finance.yahoo.com Find the latest RENALYTIX AI PLC (RTNXF) stock quote, history, news and other vital information to help you with your stock trading and investing.

Renalytix AI plc American Depositary Shares (RNLX) Stock

Nasdaq.com Renalytix AI plc American Depositary Shares (RNLX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Renalytix AI adds new biomarkers to platform for tricky to

Mobihealthnews.com 1 day ago · Renalytix AI launched KidneyIntelX in 2019 after it landed $29 million in funding. Following its launch, the company teamed up with AstraZeneca to assess the effectiveness of KidneyIntelX in improving utilization of kidney disease therapeutics among patients and to evaluate uptake and adherence to new potassium-binding agents in patients with ...

RENALYTIX AI PLC RENX Stock | London Stock Exchange

Londonstockexchange.com RENALYTIX AI PLC RENX Company page - Search stock, chart, recent trades, company information, trading information, company news, fundamentals

RNLX:NASDAQ GM Stock Quote - Renalytix AI PLC - Bloomberg

Bloomberg.com Renalytix AI PLC operates as a developer of artificial intelligence (AI). The Company offers clinical diagnostic solutions for kidney disease. Renalytix AI serves customers worldwide.

RENALYTIX AI PLC ORD 0.25P (RENX.L) Stock Price, News

Finance.yahoo.com Find the latest RENALYTIX AI PLC ORD 0.25P (RENX.L) stock quote, history, news and other vital information to help you with your stock trading and investing.

RNLX Stock Price | Renalytix AI PLC ADR Stock Quote (U.S)

Marketwatch.com Apr 01, 2021 · Renalytix AI Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded by James McCullough on …

Renalytix AI - Crunchbase Company Profile & Funding

Crunchbase.com Contact Email [email protected] Phone Number +44 (0)20 7933 8780 RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally.

Kidney diagnostics developer Renalytix AI prices US IPO at

Nasdaq.com Jul 17, 2020 · Renalytix AI, which is commercializing AI-powered diagnostic tests for kidney disease, raised $74 million by offering 5.5 million ADS equivalents at $13.50, below the as-converted last close of ...

News Releases | Renalytix AI plc

Investors.renalytixai.com Apr 08, 2021 · RNS Number : 2460R Renalytix AI PLC 04 March 2021 Renalytix AI plc ("RenalytixAI", the "Company" or the "Group") Issue of shares under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights New York , 4 March 2021 - Renalytix AI …

Renalytix AI plc (“RenalytixAI” or the “Company”) Change

Finance.yahoo.com Renalytix AI plc . www.renalytixai.com. James McCullough, CEO. Via Walbrook PR . Stifel (Nominated Adviser, Joint Broker) Tel: 020 7710 7600. Alex Price / Nicholas Moore

Renalytix AI and AstraZeneca team up to improve chronic

Mobihealthnews.com Aug 21, 2020 · Renalytix AI and AstraZeneca team up to improve chronic kidney disease outcomes Using the KidneyIntelX platform, researchers hope to create optimal utilization of existing and novel therapeutics for chronic kidney disease.

Renalytix AI plc (RNLX) Stock Price Today, Quote & News

Seekingalpha.com Jul 14, 2020 · Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial ...

Renalytix AI enters option agreement with Joslin Diabetes

Sharecast.com Apr 14, 2021 · Renalytix AI has entered into an exclusive option agreement with Joslin Diabetes Center for patent filings on additional novel biomarkers in kidney disease, it announced on Wednesday, for ...

Renalytix AI (RENX) | The Share Centre

Share.com Buying Renalytix AI Estimated breakdown Valued at 2:21am on 12 April 2021 using (at least) 15 minute delayed prices. Awaiting sale proceeds This purchase will be made when your outstanding sales order have been dealt. The market is currently closed. ...

IPO Update: Renalytix AI Proposes IPO Terms (NASDAQ:RNLX)

Seekingalpha.com Jul 14, 2020 · Cardiff, UK-based Renalytix was founded to create an artificial intelligence-based diagnostics system for kidney and potentially other chronic disease conditions.

Renalytix AI Looks For U.S. Public Capital In IPO Filing

Seekingalpha.com Jun 29, 2020 · Renalytix AI ( RNLX) has filed to raise $86.25 million in an IPO of its ADSs representing underlying ordinary shares, according to an F-1 registration statement. The firm is developing an AI ...

Renalytix AI: Time To Grow Into Its Valuation (NASDAQ:RNLX)

Seekingalpha.com Feb 11, 2021 · The basic idea on which Renalytix is so far pinning its hopes (it could have others in the future, of course) is an AI-enabled diagnostic system for kidneys. Anything that can strip the human...

RNLX Stock Forecast, Price & News (Renalytix AI) | MarketBeat

Marketbeat.com Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to ...

Shareholder Information | Renalytix AI plc

Investors.renalytixai.com The Investor Relations website contains information about Renalytix AI plc's business for stockholders, potential investors, and financial analysts.

Renalytix Ai Share Price. RENX - Stock Quote, Charts

Lse.co.uk Renalytix Ai Plc Ord 0.25P is listed on the London Stock Exchange, trading with ticker code RENX. It has a market capitalisation of £674m, with approximately 72m shares in issue. Over the last ...

RenalytixAI | LinkedIn

Linkedin.com Renalytix AI plc (LSE AIM: RENX) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical ...

Renalytix AI enters chronic kidney disease partnership

Sharecast.com Renalytix AI said the initial version of the KidneyIntelX risk score identified type-2 diabetic patients with early-stage CKD as low, intermediate or high-risk for progressive decline in kidney ...

IPO Launch: Renalytix AI Proposes U.S. IPO Terms - IPOs On

Thestreet.com Jul 16, 2020 · Renalytix AI (RNLX) aims to raise $78 million from the sale of ADSs in an IPO, according to an amended registration statement. The company …

Renalytix AI Plc - ADR to Host Earnings Call

Finance.yahoo.com Mar 02, 2021 · NEW YORK, NY / ACCESSWIRE / March 2, 2021 / Renalytix AI Plc - ADR (NASDAQ:RNLX) will be discussing their earnings results in their 2021 Second Quarter Earnings call to be held on March 2, 2021 at ...

Renalytix AI Plc - ADR Stock Forecast: up to 49.360 USD

Walletinvestor.com Renalytix AI Plc - ADR () Stock Market info Recommendations: Buy or sell Renalytix AI Plc - ADR stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Renalytix AI Plc - ADR share forecasts, stock quote and buy / sell signals below.According to present data Renalytix AI Plc - ADR's RNLX shares and potentially its market environment have been in a bullish ...

Renalytix AI PLC (RNLX) Stock Gains 8.40% This Week: Is It

Investorsobserver.com Renalytix AI PLC stock has fallen -29.29% since Thursday, July 16, 2020 when Renalytix AI PLC began trading, and the average rating from Wall Street analysts is a Buy.InvestorsObserver’s proprietary ranking system, gives RNLX stock a score of 37 out of a possible 100.. That rank is primarily influenced by a long-term technical score of 0. RNLX's rank also includes a fundamental score of 11.

Renalytix AI (RNLX) Stock Price, Quote & News | Stock Analysis

Stockanalysis.com Apr 12, 2021 · Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient ...

Renalytix AI, Mount Sinai Launch COVID-19 Kidney Disease

Aacc.org Jul 01, 2020 · In addition, Renalytix AI and Mount Sinai have formed a joint venture, Kantaro Biosciences, to increase antibody testing for SARS-CoV-2. Kantaro has entered into a deal with Bio-Techne Corporation to develop testing kits designed to measure the presence or absence of anti-SARS-CoV-2 antibodies in addition to measuring the number of antibodies a ...

SEC Filings | Renalytix AI plc

Investors.renalytixai.com The Investor Relations website contains information about Renalytix AI plc's business for stockholders, potential investors, and financial analysts.

Renalytix AI (NASDAQ:RNLX) Reaches New 52-Week High at $32

Themarketsdaily.com Mar 18, 2021 · Shares of Renalytix AI plc (NASDAQ:RNLX) reached a new 52-week high during trading on Tuesday . The stock traded as high as $32.12 and last …

Do Traders Think Renalytix AI PLC (RNLX) Can Keep Climbing

Investorsobserver.com Mar 15, 2021 · Renalytix AI PLC is a developer of artificial intelligence-enabled clinical decision support solutions for kidney disease and costly chronic medical conditions globally. The company's solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials ...

Renalytix AI (AIM:RENX) - Share price, News & Analysis

Simplywall.st Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-e ...

Critical Comparison: Biocept (NASDAQ:BIOC) versus

Themarketsdaily.com Mar 25, 2021 · Renalytix AI (NASDAQ:RNLX) and Biocept (NASDAQ:BIOC) are both small-cap computer and technology companies, but which is the superior stock?We will compare the two companies based on the strength ...

IPO Preview: Renalytix AI Seeks U.S. IPO Investment - IPOs

Thestreet.com Jun 29, 2020 · Renalytix AI (RNLX) intends to raise $86.25 million in an IPO of its ADSs representing underlying ordinary shares, according to an F-1 registration statement.